Duke Eye Center has become the first academic medical center in the country to implant a new cell-based gene therapy for a ...

ZEVASKYN ® (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis ...

Abeona Therapeutics (ABEO) announced that the Centers for Medicare and Medicaid Services has established a permanent Healthcare Common Procedure ...

We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.

Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single ...

Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only ...

A recent study published in the New England Journal of Medicine (NEJM) found that a new gene therapy drug used to cure congenital deafness was clinically effective in improving hearing for 92 ...

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

A one-time subretinal injection of Sura-vec at both high- and low-dose concentrations allowed more than half of patients with ...

Up to 60% of congenital and early-onset hearing loss is caused by genetic mutations in an inherited gene, and gene therapy ...

Up to 60% of congenital and early-onset hearing loss is caused by genetic mutations in an inherited gene, and gene therapy ...